Comparative Analysis Shows Axi-Cel Durable Treatment Benefit in R/R FL
Treatment of relapsed or refractory (R/R) follicular lymphoma (FL) with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T-cell therapy, offered substantial clinical benefit relative to existing therapeutic options...
Immune Response Muted in Patients With NHL/CLL Who Are Vaccinated Against COVID-19
Because patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), a subtype of NHL, have both a higher risk of poor outcomes from COVID-19 and immune system defects as a result of...
Certain PTCL Subtypes Benefit More From Etoposide, AHCT
The addition of etoposide to cyclophosphamide, doxorubicine, vincristine, and prednisone chemotherapy (CHOP) improved overall survival (OS) in patients with ALK+ anaplastic large T-cell lymphoma...
Glofitamab Produces Durable Responses in DLBCL
The monoclonal antibody glofitamab showed durable complete remission (CR) in patients with relapsed or refractory diffuse large B-cell lymphoma...
Nilotinib Demonstrates Greater Efficacy Than Imatinib in CML
Treatment with nilotinib was more effective in inducing deep molecular response (MR 4.5) than imatinib for patients with chronic myeloid leukemia...
Updated Results from the Phase I/II Study of Pirtobrutinib for Previously Treated CLL/SLL
Pirtobrutinib was shown to have efficacy in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with...
Addition of Brentuximab Vedotin to Chemotherapy Improves OS in Patients With Advanced-Stage HL
Adult patients with previously untreated stage III/IV classical Hodgkin lymphoma (cHL) had improved overall survival (OS) rates when treated with brentuximab vedotin plus...
Comparing Tisa-Cel to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL
As a second-line treatment for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL), the autologous CD19-targeting chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (tisa-cel) led to...
Adding Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression or Death in Newly Diagnosed DLBCL
Treatment with polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) led to a 27% reduction in the relative risk of disease...
